135 related articles for article (PubMed ID: 37949359)
1. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.
Kallionpää RA; Peltonen S; Le KM; Martikkala E; Jääskeläinen M; Fazeli E; Riihilä P; Haapaniemi P; Rokka A; Salmi M; Leivo I; Peltonen J
Lab Invest; 2024 Jan; 104(1):100285. PubMed ID: 37949359
[TBL] [Abstract][Full Text] [Related]
2. A Clinicopathologic Study on the Role of Estrogen, Progesterone, and Their Classical and Nonclassical Receptors in Cutaneous Neurofibromas of Individuals With Neurofibromatosis 1.
Rozza-de-Menezes RE; Almeida LM; Andrade-Losso RM; de Souza Vieira G; Siqueira OHK; Brum CI; Riccardi VM; Cunha KS
Am J Clin Pathol; 2021 Apr; 155(5):738-747. PubMed ID: 33289020
[TBL] [Abstract][Full Text] [Related]
3. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous neurofibroma cells with active YAP promotes proliferation of macrophages resulting in increased accumulation of macrophages by modulating CCL5 and TGF‑β1.
Jia J; Zhang H; He L; Zhang H; Shu M
Oncol Rep; 2020 Apr; 43(4):1319-1330. PubMed ID: 32323813
[TBL] [Abstract][Full Text] [Related]
5. Econazole selectively induces cell death in NF1-homozygous mutant tumor cells.
Lakes YB; Moye SL; Mo J; Tegtmeyer M; Nehme R; Charlton M; Salinas G; McKay RM; Eggan K; Le LQ
Cell Rep Med; 2023 Dec; 4(12):101309. PubMed ID: 38086379
[TBL] [Abstract][Full Text] [Related]
6. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
7. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
[TBL] [Abstract][Full Text] [Related]
8. Current and Emerging Imaging Techniques for Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas.
Li Y; Blakeley JO; Ly I; Berman Y; Lau J; Wolkenstein P; Bergqvist C; Jia W; Milner TE; Katta N; Durkin AJ; Kennedy GT; Rowland R; Romo CG; Fleming J; Kelly KM
J Invest Dermatol; 2023 Aug; 143(8):1397-1405. PubMed ID: 37330718
[TBL] [Abstract][Full Text] [Related]
9. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
10. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
11. Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.
Mazuelas H; Magallón-Lorenz M; Uriarte-Arrazola I; Negro A; Rosas I; Blanco I; Castellanos E; Lázaro C; Gel B; Carrió M; Serra E
JCI Insight; 2024 Jan; 9(3):. PubMed ID: 38175707
[TBL] [Abstract][Full Text] [Related]
12. Distinct Transcriptional Profiles in the Different Phenotypes of Neurofibroma from the Same Subject with Neurofibromatosis 1.
Wang WN; Koguchi-Yoshioka H; Nimura K; Watanabe R; Tanemura A; Fujimoto M; Wataya-Kaneda M
J Invest Dermatol; 2024 Jan; 144(1):133-141.e4. PubMed ID: 37301319
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
[TBL] [Abstract][Full Text] [Related]
14. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
[TBL] [Abstract][Full Text] [Related]
15. Vascular wall cells contribute to tumourigenesis in cutaneous neurofibromas of patients with neurofibromatosis type 1. A comparative histological, ultrastructural and immunohistochemical study.
Friedrich RE; Holstein AF; Middendorff R; Davidoff MS
Anticancer Res; 2012 May; 32(5):2139-58. PubMed ID: 22593502
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous neurofibromas: Current clinical and pathologic issues.
Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
[TBL] [Abstract][Full Text] [Related]
17. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature.
Rozza-de-Menezes RE; Brum CAI; Gaglionone NC; de Sousa Almeida LM; Andrade-Losso RM; Paiva BVB; Faveret PLS; da Silva AV; Siqueira OHK; Riccardi VM; Cunha KS
J Cutan Pathol; 2018 Oct; 45(10):743-753. PubMed ID: 29959804
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
Richey P; Funk M; Sakamoto F; Plotkin S; Ly I; Jordan J; Muzikansky A; Roberts J; Farinelli W; Levin Y; Garibyan L; Blakeley JO; Anderson RR
J Am Acad Dermatol; 2024 Apr; 90(4):767-774. PubMed ID: 38086517
[TBL] [Abstract][Full Text] [Related]
20. Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.
Karaosmanoglu B; Kocaefe ÇY; Söylemezoğlu F; Anlar B; Varan A; Vargel İ; Ayter S
Childs Nerv Syst; 2018 May; 34(5):877-882. PubMed ID: 29455242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
